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Abstract
Hereditary hypophosphatemic rickets with hypercalciuria is a rare autosomal recessive disorder (OMIM #241530),
characterized by decreased renal phosphate reabsorption that leads to hypophosphatemia, rickets, and bone pain;
hypophosphatemia is believed to stimulate 1,25 dihydroxyvitamin D synthesis which, in turn, results in hypercal-
ciuria. Hereditary hypophosphatemic rickets with hypercalciuria is caused by loss-of-function in the type 2c sodium
phosphate cotransporter encoded by the SLC34A3 gene. This report shows a family with a non-previously identi-
fied mutation in the SLC34A3 gene and exhibiting mild and different manifestations of HHRH. The probandus had
hypophosphatemia, elevated serum 1,25 dihydroxyvitamin D concentrations, high serum alkaline phosphatase
levels, hypercalciuria and nephrocalcinosis. The other members of the family presented some of these alterations:
the mother, hypercalciuria and high 1,25 dihydroxyvitamin D concentrations; the son, hypercalciuria, high 1,25
dihydroxyvitamin D values and elevated alkaline phosphatases; the father, high alkaline phosphatases. The genetic
analysis revealed the existence of a single mutation (G78R) in heterozygosis in the SLC34A3 gene in the proban-
dus, her mother and her brother, but not in the father. These findings suggest that he mutation in heterozygosis
likely gave rise to a mild phenotype with different penetrance in the three relatives and also indicates that the ele-
vation of 1,25 dihydroxyvitamin D does not result from hypophosphatemia. Thus, this family raises some issues on
the transmission and pathophysiology of hereditary hypophosphatemic rickets with hypercalciuria.
Background
Hereditary hypophosphatemic rickets with hypercal-
ciuria (HHRH) is a rare autosomal recessive disorder
(OMIM #241530), characterized by decreased renal
phosphate reabsorption that causes hypophosphatemia,
rickets, and bone pain. Hypophosphatemia stimulates
the renal 1a-hydrolase, increasing in turn the synthesis
and serum levels of 1,25 dihydroxyvitamin D, with the
resultant suppression of parathyroid hormone (PTH)
levels, increased intestinal reabsorption of calcium and
hypercalciuria, which differentiates HHRH from autoso-
mal dominant hypophosphatemic rickets (ADHR) and
X-linked hypophosphatemia (XLH).
Tieder et al. [1] described in 1985 a consanguineous
Bedouin kindred in which 6 members had hypopho-
sphatemic rickets and hypercalciuria, probably the same
disorder reported by Royer [2] in 1962 as hypercalciuric
rickets. Bergwitz et al. [3] performed a genomewide
linkage scan combined with homozygosity mapping in
the large consanguineous Bedouin kindred reported by
Tieder et al [1]. The candidate gene region was nar-
rowed to a 1.6 Mb region on chromosome 9q34, and
the mutated gene was identified as the SLC34A3, which
encodes the type 2c sodium phosphate cotransporter
(NPT2c), that, with the NPT2a, is expressed at the api-
cal domain of renal proximal tubular cells and reabsorb
phosphate from the glomerular filtrate under the hor-
monal control of PTH and the fibroblast growth factor
23 (FGF23) [4-7].
HHRH has been defined as an autosomal recessive
disorder because obligate carriers of the mutation, such
as the parents of affected children, have borderline
hypercalciuria but not hypophosphatemia or rickets [8].
However, because of the low prevalence of the disease,
the mode of inheritance has been inferred from a lim-
ited number of families worldwide. From its initial
description in 1985, few families [1,8-10] and sporadic
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Morocco, North America, Japan and Germany.
Case report
A four member Spanish family is described in this
report (Figure 1). Parents were not consanguineous and
all members were asymptomatic. The daughter was
referred to our outpatient clinic at the age of 11 years
for evaluation of hyperphosphatasia and hypercalciuria.
She had been suffering of intermittent abdominal pain
for 3 years but denied bone pain or renal colic. At the
first evaluation her height was 153.3 cm (50
th percentile)
and her weight 44.5 kg (50
th percentile), normal blood
pressure (116/60 mm Hg) and the only abnormal find-
ing in the physical examination was a mild dorsal scolio-
sis. The initial serum biochemistry in our clinic
confirmed the previous biochemical alterations and
showed decreased tubular reabsorption of phosphate
(TRP) and high circulating levels of 1,25 dihydroxyvita-
min D. Acid-base status and serum urea, creatinine,
albumin, lipid profile and liver-function tests were nor-
mal. Bilateral medullar nephrocalcinosis was found by
renal ultrasonography. No radiological signs of rickets
were present, bone mineral density was within normal
reference values and bone age was according to chrono-
logical age. Oral phosphate supplementation was pre-
scribed but only for a short period because of patient’s
bad compliance and lack of major disease-related mani-
festations. Significant biochemical findings of the patient
and her family are shown in Table 1. Renal ultrasound
of the parents and brother were normal. After a 7.5 year
follow up, the four family members continue asympto-
matic and their initial laboratory alterations remain
essentially unchanged.
The study was approved by the Ethical Committee of
our institution. The two parents gave their informed
consent to participate in the study, including the genetic
study of their children. Genomic DNA was obtained
from leukocytes in 10 ml of blood, and the 13 coding
exons and intronic flanking nucleotides of the SLC34A3
gene were amplified by polymerase chain reaction
(PCR). These PCR fragments were purified and both
DNA strands were sequenced on an automated ABI310
system (Applied Biosystems - Applera Corporation,
Drive Foster City, CA, USA).
We found a nucleotide change in exon 4 (c.418 G>A)
that results in a missense amino acid change, Glyci-
ne78Arginine (G78R). This has not been reported as a
SLC34A3 polymorphism in the genome database http://
www.ensembl.org, and the glycine 78 was conserved
among species. The c.418 A created a site for the
restriction enzyme PstI (CTGCA/G), giving two frag-
ments of 117 + 354 bp whereas the wild type allele was
s e e na sas i n g l ef r a g m e n to f4 7 1b p .W ec o n f i r m e dt h e
a b s e n c eo ft h i sp u t a t i v em u t a t i o ni n2 0 0h e a l t h yc o n -
trols by digestion of PCR fragment with PstI, followed
by electrophoresis on 3% agarose gels. The patient, her
mother and her brother were heterozygous for this
mutation and the father was wild-type homozygote.
In addition to G78R, the patient was heterozygous for
several polymorphisms (Figure 1). The patient was
homozygous for a polymorphism in the last nucleotide
of exon 8 (c.942 T>C). The patient’s mother was hetero-
zygous carrier for this exon 8 variant, while the father
and brother were also c.942 C homozygotes. Although
this change does not change the amino acid (L253L), in
silico analysis with the BDGP program http://www.fruit-
fly.org/seq_tools/splice.html predicts an effect on pre-
mRNA splicing as a result of a reduction of the score
for the splicing (0.64 vs. 0.54) at the exon 8-intron 8
boundary. Thus, the allele c.942 C might affect splicing,
skip exon 8 and produce an aberrant mRNA. To assess
the potential effect on splicing, mRNA of the proband,
their parents and brother and two healthy donors, was
obtained from peripheral leukocytes. The cDNA was
synthesized and PCR amplified with primers that
matched exons 3 and 9. We were unable to obtain
amplified product from any of the cDNAs, including the
two controls, and could not determine the putative
effect of this variant on pre-mRNA splicing.
Conclusions
This family presents phenotypic and genetic peculiarities
that deserve some comments. The mother and her two
siblings were heterozygous for a non-previously identi-
fied missense mutation in the SLC34A3 gene (c.418
G>A; G78R). The amino acid 78 of NPT2c is conserved
among species (glycine) and is located in the first mem-
brane-spanning domain of the cotransporter. The gly-
cine to arginine change likely disrupts the
transmembrane domain, resulting in an abnormal trans-
porter channel function responsible for the clinical man-
ifestations. The other nucleotide changes found in these
subjects correspond to polymorphisms. Unfortunately,
and likely as a result of the low expression of NPT2c in
leukocytes, we did not succeed in studying the potential
impact of these polymorphisms on RNA splicing. The
daughter had nephrocalcinosis, hypophosphatemia,
hypercalciuria and elevated serum 1,25 dihydroxyvitamin
D concentrations whereas her mother and brother, in
spite of carrying the same G78R mutation, only had
hypercalciuria and increased 1,25 dihydroxyvitamin D.
This indicates either the girl, and likely the father, car-
ried a second mutation out of the region analyzed, for
instance, in the promoter or intronic nucleotides that
were not sequenced or the mutation in heterozygosis
gave rise to a mild phenotype with different penetrance
in the three relatives. The last one is the most plausible
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leading to a variety of biochemical abnormalities have
already been reported in previous HHRH families [3].
The elevation of alkaline phosphatases in the father
likely corresponds to benign hyperphosphatasemia [15],
because of the absence of symptoms and the lack of
associated biochemical alterations, although accounted
for an additional source of confusion in the interpreta-
tion of the clinical picture of the family.
It is also of note that the mother and his son were
hypercalciuric and had high levels of 1,25 dihydroxyvita-
min D, particularly the mother, in the presence of nor-
mal serum concentrations of phosphate. This challenges
the pathophysiological concept that in HHRH
hypophosphatemia triggers the increased production of
1,25 dydroxyvitamin D which, in turn, causes hypercal-
ciuria. Our findings support the relationship between
elevations of 1,25 dihydroxyvitamin D and urinary cal-
cium but not the hypophosphatemia as the primary
event responsible for these alterations. It could be
hypothesized that downregulation of FGF23 serum
levels, due to decreased phosphate reabsorption, could
explain, at least partly, the elevation of the 1-25 vitamin
D. Unfortunately, FGF23 was not measured.
In summary, this report describes an additional family
with HHRH, finds a new mutation in the SLC34A3 gene
and, more interestingly, raises some issues on the genetic
basis of this disease and its pathophysiological mechanism.
Figure 1 Family pedigree showing the haplotypes and analytical findings. In addition to the c.418 G>A mutation, the genotypes for the
intron 3+c.123 C>T, exon 8 c.942 T>C, and intron 12+c.267 G>C are also indicated.
Table 1 Initial/final significant findings in the family
Patient Mother Father Brother
Age at diagnosis (years) 11 33 41 1
Serum alkaline phosphatase (Times above the upper limit of normal reference values) 4.0/2.0 0.6/1.1 2.5/1.5 1.5/3.5
Serum calcium (mg/dl) (Normal reference values: 8.5-10.5) 10.5/9.8 9.46/9.84 10.0/8.8 10.6/10.3
Serum phosphate (mg/dl) 3.2/2.3 2.6/4.3 4.2/2.8 5.3/5.0
Urine calcium/creatinine (mg/mg) (Normal reference values: <0.20) 0.45/0.21 0.33/0.27 0.17/0.04 0.52/0.34
Urine calcium (mg/kg/day) (Normal reference values: < 4.0) 9/5 6.4/NA 4.5/NA 5.5-6.2
Urine phosphate (mg/kg/day) (Normal reference values: 12.4 ± 4.6) 28.0/16.9 12.5/NA 16.1/NA 28.0/NA
Tubular reabsorption of phosphate (%) (Normal reference values: 75-85) 63.8/74.4 79.0/90.5 77.8/NA 78.1/89.9
TmP/GFR (mg/dl) (Normal reference values: 2.5-4.2) 2.1/1.8 2.1/4.2 3.3/NA 4.1/4.9
Serum intact PTH (pg/ml) (Normal reference values:10-65) 9/22 62/27 38/41 13/13
Serum 25 hydroxivitamin D (ng/ml) (Normal reference values: 10-68) 16/18 18/20.4 41/24.2 29/29
1,25 dihydroxyvitamin D (pg/ml) (Normal reference values: 20-63) 109/96 83/80 37/38 71/64
eGFR (ml/min/1.73 m
2) 104/109 83/107 84/101 144/159
Normal values for serum phosphorus: < 14 years: 3.5-6.5 mg/dl; Adults: 2.7-4.5 mg/dl. TmP/GFR values were calculated by the Walton Bijvoen nomogram. [16].
eGFR: Estimated glomerular flow rate based on Cockroft-Gault formula for adults and Schwartz formula for children. NA: not available.
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